In patients with prostate cancer (PCa), the identification of an alteration in genes associated with homologous recombination repair (HRR) has implications for prognostication, optimization of therapy, and familial risk mitigation. The aim of this study was to assess the genomic testing landscape of PCa in Canada and to recommend an approach to offering germline and tumor testing for HRR-associated genes.
The Canadian Genitourinary Research Consortium (GURC) administered a cross-sectional survey to a largely academic multidisciplinary group of investigators across 22 GURC sites between January and June 2022.
Thirty-eight investigators from all 22 sites responded to the survey. Germline genetic testing was initiated by 34%, while 45% required a referral to a genetic specialist. Most investigators (82%) reported that both germline and tumor testing was needed; with 92% currently offering germline and 72% offering tissue testing to patients with advanced PCa. The most cited reasons for not offering testing were an access gap (50%), uncertainties around who to test and which genes to test, (33%) and interpreting results (17%). A majority reported that patients with advanced PCa (74-80%) should be tested, with few investigators testing patients with localized disease except when there is a family history of PCa (45-55%).
Canadian physicians with academic subspecialist backgrounds in genitourinary malignancies recognize the benefits of both germline and somatic testing in PCa; however, there are challenges in accessing testing across practices and specialties. An algorithm to reduce uncertainty for providers when ordering genetic testing for patients with PCa is proposed.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2023 Jul 21 [Epub ahead of print]
Steven M Yip, Christopher Morash, Michael P Kolinsky, Anil Kapoor, Michael Ong, Shamini Selvarajah, Jennifer Nuk, Katie Compton, Frederic Pouliot, Luke T Lavallée, Daniel J Khalaf, Robert J Hamilton, Geoffrey T Gotto, Ricardo A Rendon, Elie Antebi, Sebastien J Hotte, Shawn Malone, Kim N Chi, Darrel E Drachenberg, Fred Saad, Jonathan Chan, Cristiano Ferrario, Jenny Ko, Bobby Shayegan, Sunil Parimi, Alan I So, Andrew Feifer, Kenneth Jansz, Daygen Finch, Joseph L Chin, Brendan Osborne, Kai Fai Ho, Corine Demanga Galamo, Anousheh Zardan, Tamim Niazi
1Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada., The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada., Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada., St Joseph's Healthcare, McMaster University, Hamilton, ON, Canada., Department of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network (UHN), Toronto, ON, Canada., Hereditary Cancer Program, BC Cancer, Vancouver, BC, Canada., Centre hospitalier universitaire de Québec, Université Laval, Quebec City, QC, Canada., Division of Urology, Department of Surgery, University of Ottawa and Ottawa Hospital Research Institute Epidemiology Program, Ottawa, ON, Canada., Department of Medicine, Medical Oncology Division, BC Cancer, Vancouver Centre, University of British Columbia, Vancouver, BC, Canada., Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada., Southern Alberta Institute of Urology, University of Calgary, Calgary, AB, Canada., Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada., Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA., Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada., BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada., Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada., Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC, Canada., Scarborough Health Network, University of Toronto, ON, Canada., Jewish General Hospital, McGill University, Montreal, QC, Canada., Department of Medical Oncology, BC Cancer - Abbotsford, Abbotsford, BC, Canada., Department of Medical Oncology, BC Cancer-Victoria, BC, Canada., Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Division of Urology, Department of Surgery, University of Toronto, Toronto, ON Canada., Joseph Brant Hospital, McMaster University, Burlington, ON, Canada., Department of Medical Oncology, BC Cancer Agency - Centre for the Southern Interior, Kelowna, BC, Canada., Department of Surgery (Urology), University of Western Ontario, London Health Sciences Center, London, ON, Canada., Medical Affairs, Janssen Inc, Toronto, ON, Canada., STAT-TU Inc., Elora, Ontario, Canada.